ArticleCurrent oncology (Toronto, Ont.)2011
Immune therapy for breast cancer in 2010-hype or hope?
Article in Current oncology (Toronto, Ont.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 52 citations in OpenAlex.
- Bridging molecular insights and clinical application: non-coding RNAs, targeted drug delivery, and metastatic breast cancer therapy.Discover oncology · 2025Review
- Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.Nano research · 2025Article
- Breast Cancer: Targeting of Steroid Hormones in Cancerogenesis and Diagnostics.International journal of molecular sciences · 2021Review
- Evaluation of Breast Cancer (BC) Awareness among Female University Students in Zarqa University, Jordan.European journal of breast health · 2018Article
- Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer.Neoplasia (New York, N.Y.) · 2015Article
- Prevalence of BRCA1 gene mutation in breast cancer patients in Guangxi, China.International journal of clinical and experimental pathology · 2014Article
- Dracorhodin perchlorate induced human breast cancer MCF-7 apoptosis through mitochondrial pathways.International journal of medical sciences · 2013Article
- T cell coinhibition and immunotherapy in human breast cancer.Discovery medicine · 2012Review
- Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.BMC cancer · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of numerous breast cancer antigens has generated increasing enthusiasm for the application of immune-based therapies in breast malignancies. Although the use of monoclonal antibodies has revolutionized the "targeted therapy" of breast cancer, and the immunomodulatory effects of bisphosphonates continue to be evaluated, few studies to date have demonstrated widespread utility for other forms of immunotherapy. The present review assesses modern research and explores whether the hopes for immunotherapy can overcome the hype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.